Streetbeat News

Revenues

TRNO

Terreno Realty Corporation (TRNO) sold an industrial property in Seattle, WA, for $11M, generating a 16.5% internal rate of return. The property, acquired in 2016 for $4.7M, is fully leased. TRNO operates in six major U.S. coastal markets.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:16 pm

INCR

InterCure announced its preliminary 2023 revenue of NIS 351 million and EBITDA of over NIS 50 million. This financial update is significant for investors tracking the company's performance.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:12 pm

BLRX

BioLineRx Ltd. announced a registered direct offering of 7.5M ADSs and warrants to purchase up to 7.5M ADSs at $0.80 each, aiming to raise $6M. The proceeds will support the commercialization of APHEXDA® for stem cell mobilization in multiple myeloma patients, advance pancreatic cancer clinical development, and other programs. The offering, facilitated by JonesTrading Institutional Services LLC, is expected to close by April 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:02 pm

WAL

Recent analysis of Western Alliance (NYSE:WAL) by 6 financial analysts shows a mix of bullish to bearish sentiments, with an upward trend in the 12-month price targets, now averaging $81.33. The company, a Las Vegas-based bank holding company, faces challenges in revenue growth and debt management but excels in net margin, ROE, and ROA. Analysts maintain or raise their ratings, reflecting their reaction to the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:01 pm

DOC

Healthpeak Properties (NYSE:DOC) has been analyzed by 3 analysts, showing diverse opinions with recent ratings ranging from bullish to indifferent. The average 12-month price target for DOC has been raised to $21.67, indicating a 20.39% increase from the previous target. The company's financial health appears strong, with positive revenue growth, high net margin, and effective debt management. Analysts' actions and price target adjustments reflect their response to Healthpeak's market performance and financial indicators.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:00 pm

MRK

Analysts have recently updated their ratings and price targets for Merck & Co (NYSE:MRK), showing a diverse range of opinions but generally positive sentiment. The average 12-month price target has been raised to $134.88, indicating a 3.66% increase from the previous target. The company's financial performance shows a positive revenue trend with a growth rate of 5.78% as of December 31, 2023, but it faces challenges in net margin, ROE, and ROA, which are below industry averages. Merck's strong market presence and substantial size are highlighted by its market capitalization and sound financial structure, as evidenced by a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:00 pm

PB

Prosperity Bancshares (NYSE:PB) received mixed analyst ratings with a shift towards a more bullish outlook in the last quarter. The average 12-month price target is $72.4, indicating a 3.43% increase from the previous target. The company faces revenue challenges with a -7.51% decline but shows strong profitability with a high net margin of 36.33%. Concerns include a high debt-to-equity ratio of 0.53 and below-average ROE of 1.35%.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 1:00 pm

BABA

GDX

JD

LI

NIO

China's March manufacturing activity surged to a 13-month high, with the Caixin China General Manufacturing PMI reaching 51.1, indicating expansion. This growth spurred rallies in Chinese company shares and metal commodities. However, concerns were raised about potential deflationary pressures and trade tensions due to increased production aimed at global markets. Chinese stocks listed in New York and the VanEck Gold Miners ETF saw premarket gains, while gold and copper prices also rose.

Portfolio Pulse from Piero Cingari

April 01, 2024 | 12:58 pm

JAGX

Jaguar Health (NASDAQ:JAGX) reported a decrease in Q4 EPS to $0.42 from $0.57 YoY, but sales surged to $2.30B, significantly beating the $2.61M estimate and marking a 70.45K percent increase from last year's $3.26M.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:46 pm

SGML

Sigma Lithium announces a final investment decision to double its production capacity to 520,000 tonnes/year with a $100M investment in Phase 2 of its Industrial Greentech Plant. The expansion aims to power 1.8 million EVs and is expected to be completed in 10 months, with construction starting in 4Q24. The company plans to finance the expansion with existing cash and future cash flow from lithium concentrate shipments. Sigma Lithium ended its first production year with positive cash adjusted EBITDA and operating profit, despite a decline in lithium prices.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:39 pm